Relmada Therapeutics, Inc.
Clinical trials sponsored by Relmada Therapeutics, Inc., explained in plain language.
Clinical-stage biopharmaceutical company developing therapies for central nervous system disorders.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
Could a new drug offer hope for Treatment-Resistant depression?
Disease control Expanded access (ended)This program provides access to esmethadone (REL-1017), an experimental drug, for people with serious depression who have not responded to standard treatments and cannot join other clinical trials. The goal is to offer a potential treatment option when no satisfactory alternative…
Sponsor: Relmada Therapeutics, Inc. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Bladder cancer drug trial pulled before it even started
Disease control CancelledThis was a planned Phase 3 study testing NDV-01, a combination of two chemotherapy drugs (gemcitabine and docetaxel) given directly into the bladder, for people with a type of bladder cancer that did not respond to BCG therapy. The trial was withdrawn before enrolling any partici…
Phase 3 • Sponsor: Relmada Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Bladder cancer drug trial pulled before it even started
Disease control CancelledThis was a planned Phase 3 study comparing a new drug, NDV-01 (a combination of two chemotherapy drugs), against simple observation in people with intermediate-risk non-muscle invasive bladder cancer. The goal was to see if the drug could prevent the cancer from coming back after…
Phase 3 • Sponsor: Relmada Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC